Back to News
Market Impact: 0.32
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCorporate Guidance & OutlookProduct Launches
Exelixis reported solid earnings and outlined plans to further expand its CABOMETYX franchise. Management is also preparing for a potential late-year launch of zanzalintinib (zanza) for colorectal cancer, which could provide an additional growth catalyst for the oncology portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
EXEL0.55
More News
- Trump called out Big Oil profits. Here’s how much their refining earnings have surged since
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Wall Street Punishes Tech Stocks on Earnings Misses
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Intel’s stock crashes, knocking $12B from government’s stake
- Intel plunged 28.6% for its worst drop since 1974 — and the AI sell-off gave the S&P 500 its worst day since June